<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A grading system (grades 1-3) for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) is used in the WHO classification for lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> based on the absolute number of centroblasts in the neoplastic follicles </plain></SENT>
<SENT sid="1" pm="."><plain>Grade 3 FL is further subdivided into 3a and 3b depending on the presence or absence of centrocytes </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 231 patients with FL, referred from 1970 to 2001, were identified from our prospectively maintained database </plain></SENT>
<SENT sid="3" pm="."><plain>Original diagnostic materials were available for review on 215 patients and these were reclassified according to the WHO grading system </plain></SENT>
<SENT sid="4" pm="."><plain>Follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grades 1, 2 and 3 accounted for 92, 68 and 55 patients, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>No significant overall survival (OS) differences were observed among FL grades 1-3 (log rank P=0.25) or between grades 3a and 3b (log rank P=0.20) </plain></SENT>
<SENT sid="6" pm="."><plain>No significant failure-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e>) differences were observed among FL grades 1-3 (log rank P=0.72) or between grades 3a and 3b (log rank P=0.11) </plain></SENT>
<SENT sid="7" pm="."><plain>First-line <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> did not influence OS or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e> (log rank P=0.86, P=0.58, respectively) in patients with FL grade 3 </plain></SENT>
<SENT sid="8" pm="."><plain>There are long-term survivors among patients with FL grade 3 with a continuing risk of relapse </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="48120">Anthracyclines</z:chebi> did not appear to influence survival or disease relapses when given as front-line therapy in our series </plain></SENT>
<SENT sid="10" pm="."><plain>The role of <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> should be further evaluated in large randomised studies </plain></SENT>
</text></document>